Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab effects on eosinophil activation and lung microbiome in severe eosinophilic asthma
2017-003665-10Phase 4Unknown
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by Royal Brompton and Harefield hospitals. Primary endpoint: Bronchial tissue eosinophil density. Status: unknown.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2017-003665-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003665-10.